Cover Image

Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation

This study evaluate the potential of plasmatic CXCL-10 (pCXCL-10) as a pre&post transplantation prognostic and diagnostic biomarker of T-cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR) and subclinical rejection (SCR) risk in adult kidney recipients considering BKV and CMV infe...

Full description

Saved in:
Bibliographic Details
Main Authors: Millán, Olga (Author) , Rovira, Jordi (Author) , Guirado, Lluis (Author) , Espinosa, Cristina (Author) , Budde, Klemens (Author) , Sommerer, Claudia (Author) , Piñeiro, Gaston J. (Author) , Diekmann, Fritz (Author) , Brunet, Mercè (Author)
Format: Article (Journal)
Language:English
Published: 2 July 2021
In: Clinical immunology
Year: 2021, Volume: 229, Pages: 1-12
ISSN:1521-7035
DOI:10.1016/j.clim.2021.108792
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.clim.2021.108792
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1521661621001297
Get full text
Author Notes:Olga Millán, Jordi Rovira, Lluis Guirado, Cristina Espinosa, Klemens Budde, Claudia Sommerer, Gaston J. Piñeiro, Fritz Diekmann, Mercè Brunet
Description
Summary:This study evaluate the potential of plasmatic CXCL-10 (pCXCL-10) as a pre&post transplantation prognostic and diagnostic biomarker of T-cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR) and subclinical rejection (SCR) risk in adult kidney recipients considering BKV and CMV infections as possible clinical confounder factors. Twenty-eight of 100 patients included experienced rejection (TCMR:14; ABMR:14); 8 SCR; 13 and 16 were diagnosed with BKV and CMV infection, respectively. Pre-transplantation pCXCL-10 was significantly increased in TCMR and ABMR and post-transplantation in TCMR, ABMR and SCR compared with nonrejectors. All CMV+ patients showed pCXCL-10 levels above the cutoff values established for rejection whereas the 80% of BKV+ patients showed pCXCL-10 concentration < 100 pg/mL. pCXCL-10 could improve pre-transplantation patient stratification and immunosuppressive treatment selection according to rejection risk; and after kidney transplantation could be a potential early prognostic biomarker for rejection. Clinical confounding factor in BKV+ and particularly in CMV+ patients must be discarded.
Item Description:Gesehen am 21.10.2021
Physical Description:Online Resource
ISSN:1521-7035
DOI:10.1016/j.clim.2021.108792

Similar Items